Compositions and methods for increasing bone mineralization

Details Compositions and methods for increasing bone mineralization Compositions and methods for increasing bone mineralization

2011-07-12

2011-07-12

Kam, Chih-Min (Department: 1656)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S350000, C530S324000, C536S023100, C435S069100

Reexamination Certificate

active

07977312

ABSTRACT:
A novel class or family of TGF-β binding proteins is disclosed. Also disclosed are assays for selecting molecules for increasing bone mineralization and methods for utilizing such molecules.

REFERENCES:
patent: 4331647 (1982-05-01), Goldenberg
patent: 4376110 (1983-03-01), David et al.
patent: 4411993 (1983-10-01), Gillis
patent: 4427115 (1984-01-01), Laipply
patent: 4543439 (1985-09-01), Frackelton, Jr. et al.
patent: RE32011 (1985-10-01), Zimmerman et al.
patent: 4837440 (1989-06-01), Burtscher et al.
patent: 4902614 (1990-02-01), Wakabayashi et al.
patent: 5070108 (1991-12-01), Margolis
patent: 5145684 (1992-09-01), Liversidge et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5399363 (1995-03-01), Liversidge et al.
patent: 5453492 (1995-09-01), Butzow et al.
patent: 5466468 (1995-11-01), Schneider et al.
patent: 5543158 (1996-08-01), Gref et al.
patent: 5552157 (1996-09-01), Yagi et al.
patent: 5565213 (1996-10-01), Nakamori et al.
patent: 5567434 (1996-10-01), Szoka, Jr.
patent: 5627052 (1997-05-01), Schrader et al.
patent: 5641515 (1997-06-01), Ramtoola et al.
patent: 5698426 (1997-12-01), Huse
patent: 5738868 (1998-04-01), Shinkarenko
patent: 5780263 (1998-07-01), Hastings et al.
patent: 5795587 (1998-08-01), Gao et al.
patent: 5811238 (1998-09-01), Stemmer et al.
patent: 5830721 (1998-11-01), Stemmer et al.
patent: 5837458 (1998-11-01), Minshull et al.
patent: 5877397 (1999-03-01), Lonberg et al.
patent: 6054561 (2000-04-01), Ring
patent: 6057421 (2000-05-01), Muller et al.
patent: 6117911 (2000-09-01), Grainger et al.
patent: 6133426 (2000-10-01), Gonzalez et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6207153 (2001-03-01), Dan et al.
patent: 6395511 (2002-05-01), Brunkow et al.
patent: 6489445 (2002-12-01), Brunkow et al.
patent: 6495736 (2002-12-01), Brunkow et al.
patent: 6703199 (2004-03-01), Koide
patent: 6803453 (2004-10-01), Brunkow et al.
patent: 6806055 (2004-10-01), Berman et al.
patent: 6815201 (2004-11-01), Pinter
patent: 6818748 (2004-11-01), Fulton et al.
patent: 7192583 (2007-03-01), Brunkow et al.
patent: 2003/0165410 (2003-09-01), Taylor
patent: 2003/0186915 (2003-10-01), Pan et al.
patent: 2004/0009535 (2004-01-01), Brunkow et al.
patent: 2004/0023356 (2004-02-01), Krumlauf et al.
patent: 2004/0058321 (2004-03-01), Brunkow et al.
patent: 2004/0141875 (2004-07-01), Doshi
patent: 2004/0146888 (2004-07-01), Paszty et al.
patent: 2004/0158045 (2004-08-01), Brunkow et al.
patent: 2005/0106683 (2005-05-01), Winkler et al.
patent: 2005/0238646 (2005-10-01), Ledbetter et al.
patent: 2006/0233801 (2006-10-01), Brunkow et al.
patent: 2007/0110747 (2007-05-01), Paszty et al.
patent: 2007/0292444 (2007-12-01), Krumlauf et al.
patent: 102 55 152 (2004-06-01), None
patent: 2 838 379 (2003-10-01), None
patent: 4-141095 (1992-05-01), None
patent: WO-91/13152 (1991-09-01), None
patent: WO-92/02551 (1992-02-01), None
patent: WO-92/06693 (1992-04-01), None
patent: WO-95/30003 (1995-11-01), None
patent: WO-98/21335 (1998-05-01), None
patent: WO-99/03996 (1999-01-01), None
patent: WO-99/06554 (1999-02-01), None
patent: WO-99/15556 (1999-04-01), None
patent: WO-00/32773 (2000-06-01), None
patent: WO-00/75317 (2000-12-01), None
patent: WO-01/64885 (2001-09-01), None
patent: WO-01/92308 (2001-12-01), None
patent: WO-01/98491 (2001-12-01), None
patent: WO-02/24888 (2002-03-01), None
patent: WO-03/106657 (2003-12-01), None
patent: WO-2005/003158 (2005-01-01), None
patent: WO-2005/014650 (2005-02-01), None
Eli Lilly Statement of Grounds of Appeal, Opposition to European Patent Application No. 1133558 B1, dated Sep. 28, 2009.
Declaration filed in connection with the European Patent EP 1133558 Opposition, Expert opinion of Prof. Dr. Thomas Muller, dated Sep. 23, 2009.
Winkler et al., Osteocyte control of bone formation via sclerostin, a novel BMP antagonist,EMBO J.22(23): 6267-76 (2003).
van Bezooijen et al., SOST/sclerostin, an osteocyte-derived negative regulator of bone formation,Cytokine Growth Factor Rev., 16: 319-27 (2005).
van Bezooijen et al., Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation,J. Bone Min. Res.22: 19-28 (2007).
van Bezooijen et al., Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist,J. Exp. Med.199(6): 805-14 (2004).
Li et al., Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling,J. Biol. Chem.280(20): 19883-7 (2005).
Declaration filed in connection with the European Patent EP 1133558 Opposition, Expert opinion of Dr. Walter Sebald, dated Sep. 24, 2009.
Kirsch et al., BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II,EMBO J.19(13): 3314-24 (2000).
Heinecke et al., Receptor oligomerization and beyond: A case study in bone morphogenetic proteins,BMC Biol.7: 59 (2009).
Declaration filed in connection with the European Patent EP 1133558 Opposition, Expert opinion of Prof. Dr. Edgar Wingender, dated Sep. 24, 2009.
Mayer et al., Differentiation of osteogenetic cells: Systems and regulators,Z. Orthop., 130: 276-84 (1992)—Abstract Only.
Blum et al., Study plan for German students in the summer of 1998, University Bioinformatik lecture announcement (1998).
Baxevanis (Ed.) et al., Bioinformatics: A practical guide to the analysis of genes and proteins, John Wiley & Sons, Inc. p. 234 (1998).
Bishop (Ed.), Guide to Human Genome Computing, Second Edition, Academic Press, Chapter 1: Introduction to human genome computer via the world wide web, pp. 1-14 (2003).
Declaration filed in connection with the European Patent EP 1133558 Opposition, Expert opinion of Dr. Auristela Freire de Paes Alves, Ph.D., dated Sep. 9, 2009.
Eli Lilly, Biacore experiment comparison results, Setup assay to measure BMP binding to captured SOST, dated Sep. 28, 2009.
Alting-Mees et al., “Monoclonal Antibody Expression Libraries: A Rapid Alternative to Hybridomas,”Strategies in Molecular Biology, 3:1-9 (1990).
Alves et al., “Sclerosteosis: A Marker of Dutch Ancestry?”Rev. Bras. Genet., 4:825-834 (1982).
Angal et al., “A Single Amino Acid Substitution Abolishes the Heterogeneity of Chimeric Mouse/Human (IgG4) Antibody,”Mol. Immunol., 30(1):105-108 (1993).
Avsian-Kretcher et al., “Comparative Genomic Analysis of the Eight-Membered Ring Cystine Knot-Containing Bone Morphogenetic Protein Antagonists,”Mol. Endo., 18(1):1-12 (2004).
Babcook et al., “A Novel Strategy for Generating Monoclonal Antibodies from Single, Isolated Lymphocytes Producing Antibodies of Defined Specificities,”Proc. Natl. Acad. Sci.(USA), 93:7843-7848 (1996).
Baines et al., “Purification of Immunoglobulin G (IgG),” Methods in Molecular Biology, 10:79-104, The Humana Press, Inc. (1992).
Balemans et al., “Extracellular Regulation of BMP Signaling in Vertebrates: A Cocktail of Modulators,”Dev. Biol., 250:231-250 (2002).
Balemans et al., “Increased Bone Density in Sclerosteosis is due to the Deficiency of a Novel Secreted Protein (SOST),”Hum. Mol. Genet., 10:537-543 (2001).
Beighton et al., “The Clinical Features of Sclerosteosis,”Annals of Internal Medicine, 84:393-397 (1976).
Beighton et al., “The Syndromic Status of Sclerosteosis and van Buchem Disease,”Clinical Genetics, 25:175-181 (1984).
Bendayan, M., “Possibilities of False Immunocytochemical Results Generated by the Use of Monoclonal Antibodies: The Example of the Anti-proinsulin Antibody,”J. Histochem. Cytochem., 43(9): 881-886 (1995).
Berman et al., “The Protein Data Bank,”Acta. Cryst., 58(10:899-907 (2002).
Bird et al., “Single-Chain Antigen-Binding Proteins,”Science, 242:423-426 (1988).
Birren et al., “Homo Sapiens chromosome 17, clone RP5-905N1,”EMBL Sequence Database, AC003098.2 (2006).
Black et al., “A Somatic Cell Hybrid Map of the Long Arm of Human Chromosome 17, Containing the Familial Breast Cancer Locus (BRCAI),”Am. J Hum. Genet., 52:702-710 (1

Affiliated with

Also associated with

Rating

Compositions and methods for increasing bone mineralization does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for increasing bone mineralization, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for increasing bone mineralization will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2619793